Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Protalix BioTherapeutics, Inc. (PLX) had Revenue of $53.40M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$53.40M
Net Income	$2.93M
Cost of Goods Sold	$24.32M
Gross Profit	$29.08M
Operating Expenses	$49.48M
Operating Income	$3.92M
Non-Operating Income/Expense	$0.24M
Pre-Tax Income	$4.15M
Normalized Pre-Tax Income	$4.15M
Income after Taxes	$2.93M
Income from Continuous Operations	$2.93M
Consolidated Net Income/Loss	$2.93M
Normalized Income after Taxes	$2.93M
EBIT	$3.92M
EBITDA	$5.22M
Weighted-Average Shares Outstanding (Basic)	72.53M
Weighted-Average Shares Outstanding (Diluted)	81.06M
Earnings per Share (EPS) (Basic)	$0.04
Earnings per Share (EPS) (Diluted)	$0.04
Balance Sheet Financials
Current Assets	$60.08M
Property, Plant, and Equipment	$4.59M
Long-Term Assets	$13.34M
Total Assets	$73.42M
Current Liabilities	$25.62M
Long-Term Debt	--
Long-Term Liabilities	$4.58M
Total Liabilities	$30.21M
Common Equity	$43.21M
Tangible Shareholders Equity	$43.21M
Shareholders Equity	$43.21M
Common Shares Outstanding	75.85M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$8.67M
Cash Flow from Investing Activities	$4.22M
Cash Flow from Financial Activities	$-16.79M
Beginning Cash	$23.63M
End Cash	$19.76M
Increase/Decrease in Cash	$-3.87M
Stock-Based Compensation	$3.25M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.34
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	54.46%
Operating Margin	7.34%
EBIT Margin	7.34%
EBITDA Margin	9.78%
Pre-Tax Profit Margin	7.78%
Profit Margin	5.49%
Free Cash Flow	$7.39M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.73
Inventory Turnover	1.14
Receiveable Turnover	18.36
Days Sales in Receivables	19.88
Return on Equity	6.79%
Return on Tangible Equity	6.79%
Return on Assets	3.99%
Return on Investments	6.79%
Book Value Per Share	$0.57
Free Cash Flow per Share	$0.09
Operating Cash Flow per Share	$0.11

Data from Zacks Investment Research, Inc.